Abstract
High mobility group box 1 (HMGB1) is a nuclear DNA-binding protein with a dual role in cancer, acting as an oncogene and a tumor suppressor. This protein regulates nucleosomal structure, DNA damage repair, and genomic stability within the cell, while also playing a role in immune cell functions. This review comprehensively evaluates the biological and clinical significance of HMGB1 in cancer, including its involvement in cell death and survival, its potential as a therapeutic target and cancer biomarker, and as a prosurvival signal for the remaining cells after exposure to cytotoxic anticancer treatments. We highlight the need for a better understanding of the cellular markers and mechanisms involved in the involvement of HMGB1 in cancer, and aim to provide a deeper understanding of its role in cancer progression.
Introduction
High Mobility Group Box 1 (HMGB1) is a versatile protein that functions as a "double-edged sword" in oncology. Originally identified as a non-histone nuclear protein responsible for maintaining DNA architecture and genomic stability, its role shifts dramatically when it is released into the extracellular space. In the tumor microenvironment, HMGB1 acts as a Danger-Associated Molecular Pattern (DAMP), influencing cancer progression, metastasis, and the efficacy of therapeutic interventions. This review synthesizes current research to map the complex "Jekyll and Hyde" nature of HMGB1, governed by its cellular localization and chemical (redox) state.
Structural Basis and Redox Regulation
The functional versatility of HMGB1 is rooted in its tripartite structure, consisting of two DNA-binding domains (A-box and B-box) and a negatively charged C-terminal acidic tail. The A-box typically acts as an antagonist to the pro-inflammatory B-box. Crucially, the protein's activity is dictated by the redox state of three conserved cysteine residues (C23, C45, and C106).
As illustrated in the figure above, the redox state acts as a molecular switch:
- Reduced HMGB1 (all-thiol): Functions primarily as a chemoattractant, recruiting leukocytes to the tumor site.
- Disulfide HMGB1: Acts as a potent pro-inflammatory cytokine by binding to receptors like TLR4.
- Oxidized HMGB1: Generally loses its immunological activity, suggesting that the metabolic state of the tumor microenvironment directly modulates HMGB1 signaling.
The Paradox: Tumor Promoting vs. Antitumor Activity
HMGB1 exhibits context-dependent effects on tumor growth. While it can promote antitumor immunity under specific conditions—such as facilitating the maturation of dendritic cells (DCs) as a DAMP—it more frequently drives oncogenic processes through several key pathways.
Tumor-Promoting Mechanisms
- Proliferation and Stemness: HMGB1 promotes the self-renewal of Cancer Stem Cells (CSCs) through TLR2/4 and Yap signaling, contributing to tumor recurrence.
- Autophagy and Survival: A critical mechanism of resistance is HMGB1-induced autophagy. By promoting cellular "self-eating," HMGB1 helps cancer cells survive metabolic stress and DNA damage induced by chemotherapy and radiation.
- Metastasis and Angiogenesis: HMGB1 upregulates Matrix Metallopeptidases (MMPs) and triggers pathways like RAGE/NF-κB and PI3K/AKT to facilitate tissue invasion and the formation of new blood vessels.
- Immune Evasion: Beyond its pro-inflammatory roles, HMGB1 can induce immunotolerance by expanding Regulatory B cells (Bregs) and promoting M2 macrophage polarization, effectively shielding the tumor from the host’s immune system.
Clinical Significance and Therapeutic Potential
High expression levels of HMGB1 are consistently linked to poor prognosis and resistance to standard treatments, including Adriamycin, Cisplatin, and Taxanes. For example, in gastric cancer, HMGB1-mediated IL-8 secretion is a known driver of both angiogenesis and drug evasion.
Targeting the HMGB1 axis represents a promising frontier in cancer therapy. Several strategies are under investigation:
- Small Molecule Inhibitors: Compounds like SB17170 aim to block HMGB1’s interaction with its receptors.
- Decoy Receptors: Fusion proteins such as CD24Fc are being explored to sequester extracellular HMGB1 and sensitize tumors to conventional therapies.
Conclusion
The "HMGB1 paradox" remains a significant challenge in oncology. While its role as a genomic stabilizer is beneficial, its extracellular functions often favor tumor progression and treatment resistance. Future research must focus on the real-time tracking of HMGB1’s redox dynamics in vivo and the development of selective inhibitors that can disrupt pro-tumor signaling without compromising beneficial immune responses.
Summary updated